ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF SODIUM PHENYLBUTYRATE AND TAURURSODIOL BY USING RP-HPLC IN BULK AND PHARMACEUTICAL DOSAGE FORM

SUNIL RAYUDU; M. MANORANJANI; D. ANITHA

doi:10.22159/ijap.2026v18i1.55081

Authors

SUNIL RAYUDU Department of Chemistry, Krishna University, Machilipatnam-521004, AP, India https://orcid.org/0000-0002-8635-3717
M. MANORANJANI Department of Chemistry, PB Siddhartha College of Arts & Science, Vijayawada-520010, AP, India
D. ANITHA Dhanekula Institute of Engineering and Technology (DIET), Vijayawada, AP, India

DOI:

https://doi.org/10.22159/ijap.2026v18i1.55081

Keywords:

Sodium phenylbutyrate, Taurursodiol, RP-HPLC, Development, Validation

Abstract

Objective: In order to assess Sodium Phenylbutyrate and Taurursodiol, two active pharmaceutical components, simultaneously, this study set out to create and validate a new RP-HPLC (Reverse Phase High Performance Liquid Chromatography) technique that was simple, responsive, and stable.

Methods: An X-bridge phenyl column with dimensions 150x4.6 mm and a 3.5 µ was used in the chromatographic approach. The mobile phase consisted of acetonitrile and 0.1% triethyl amine with a pH of 2.5, adjusted with OPA (Ortho Phosphoric Acid) in a ratio of 40:60. Isocratic elution was used. The instrumental conditions were set to 1.0 mL/min with a detection wavelength of 266 nm using the PDA (Photo Diode Array) detector. Validation of the proposed method was carried out according to an international conference on harmonization (ICH) guidelines.

Results: The calibration curves were linear, with a regression coefficient (R²) value of 0.999 and concentrations ranging from 75 to 450 µg/mL of Sodium phenylbutyrate and 25–150 µg/mL of Taurursodiol. The method’s LOD (Limit Of Detection) and LOQ (Limit Of Quantification) were 0.63 µg/mL, 0.21 µg/mL, and 2.1 µg/mL, 0.7 µg/mL for Sodium Phenylbutyrate and Taurursodiol respectively.

Conclusion: The proposed method to be fast, simple, feasible and affordable in assay condition. During stability tests, it can be used for routine analysis of production samples and to verify the quality of drug samples during stability studies.

References

1. Merritt J L, Brody L L, Pino G, Rinaldo P. Newborn screening for proximal urea cycle disorders: Current evidence supporting recommendations for newborn screening. Mol Genet Metab 2018; 124: 109–13. doi:10.1016/j.ymgme.2018.04.006

2. Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, Giorgi FM. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability. Genes 2020; 11: 556–604. doi:10.3390/genes11050556

3. Shahbazi J, Liu Y, Atmadibrata B, Bradner JE, Marshall GM, Lock RB, Liu T. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clin Cancer Res 2016; 22: 2534–44. doi:10.1158/1078-0432.CCR-15-1666

4. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet 2021; 397: 2195–211. doi:10.1016/s0140-6736(20)32542-3

5. Xu X, Zhang X, Zhang G, Abbasi Tadi D. Prevalence of antibiotic resistance of Staphylococcus aureus in cystic fibrosis infection: a systematic review and meta-analysis. J Glob Antimicrob Resist 2024; 36: 419–25. doi:10.1016/j.jgar.2023.05.006

6. Motta Ana Paula Gobbo, Rigobello Mayara Carvalho Godinho, Silveira Renata Cristina de Campos Pereira, Gimenes Fernanda Raphael Escobar. Nasogastric/nasoenteric tube-related adverse events: an integrative review. Rev Lat Am Enfermagem 2021; 29: e3400. doi:10.1590/1518-8345.3355.3400

7. Kodua Michael, Mackenzie Jay-Marie, Smyth Nina. Nursing assistants' experiences of administering manual restraint for compulsory nasogastric feeding of young persons with anorexia nervosa. Int J Ment Health Nurs 2020; 29: 1181–91. doi:10.1111/inm.12758

8. Mukherjee Arghya, Singh Santosh. Andrographolide prevents acute hyperammonemia-induced motor dysfunction in rats. Evidences for its mechanism of action. Phytomedicine Plus 2024; 100679. doi:10.1016/j.phyplu.2024.100679

9. McGlacken-Byrne Sinéad M, Conway Gerard S. Premature ovarian insufficiency. Best Practice & Research. Clinical Obstetrics & Gynaecology 2021; 81: S1521–6934: 00167–X. doi:10.1016/j.bpobgyn.2021.09.011

10. Seppä Satu, Kuiri-Hänninen Tanja, Holopainen Elina, Voutilainen Raimo. Management of endocrine disease: Diagnosis and management of primary amenorrhea and female delayed puberty. Eur J Endocrinol 2021; 184: R225 – R42. doi:10.1530/EJE-20-1487

11. Bernstein H, Bernstein C. Bile acids as carcinogens in the colon and at other sites in the gastrointestinal system. Exp Biol Med (Maywood) 2023; 248: 79–89. doi:10.1177/15353702221131858

12. Masato Anna, Plotegher Nicoletta, Boassa Daniela, Bubacco Luigi. Impaired dopamine metabolism in Parkinson's disease pathogenesis. Mol Neurodegener 2019; 14: 35. doi:10.1186/s13024-019-0332-6

13. Martinez M, Harding CO, Schwank G, Thöny B. (January 2024). State-of-the-art 2023 on gene therapy for phenylketonuria. J Inherit Metab Dis 2023; 47: 80–92. doi:10.1002/jimd.12651

14. Ashe K, Kelso W, Farrand S, Panetta J, Fazio T, De Jong G, Walterfang M. Psychiatric and Cognitive Aspects of Phenylketonuria: The Limitations of Diet and Promise of New Treatments. Front Psychiatry 2019; 10: 561. doi:10.3389/fpsyt.2019.00561

15. Chiang JY, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol 2020; 318: G554 – G73. doi:10.1152/ajpgi.00223.2019

16. Shapiro Hagit, Kolodziejczyk Aleksandra A, Halstuch Daniel, Elinav Eran. Bile acids in glucose metabolism in health and disease. Journal of Experimental Medicine 2018; 215: 383–96. doi:10.1084/jem.20171965

17. Petersen KS, Kris-Etherton PM. Diet quality assessment and the relationship between diet quality and cardiovascular disease risk. Nutrients 2021; 13: 4305. doi:10.3390/nu13124305

18. Adler A, Agodoa L, Algra A, Asselbergs FW, Beckett NS, Berge E, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021; 397: 1625–36. doi:10.1016/S0140-6736(21)00590-0

19. Handsaker RE, Kashin S, Reed NM, Tan S, Lee WS, McDonald TM, et al. Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease. Cell 2025; 188: 623–39.e19. doi:10.1016/j.cell.2024.11.038

20. McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol 2018; 25: 24–34. doi:10.1111/ene.13413

21. Alborghetti M, Nicoletti F. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. Curr Neuropharmacol 2019; 17: 861–73. doi:10.2174/1570159X16666180830100754

22. Abusrair AH, Elsekaily W, Bohlega S. Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies. Tremor Other Hyperkinet Mov 2022; 12: 29. doi:10.5334/tohm.712

23. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. European Journal of Neurology 2020; 27: 1918–29. doi:10.1111/ene.14393

24. Vitturi BK, Montecucco A, Rahmani A, Dini G, Durando P. Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis. Front Public Health 2023; 11. doi:10.3389/fpubh.2023.1285103

25. Tateishi H, Monde K, Anraku K, Koga R, Hayashi Y, Ciftci HI, et al. A clue to unprecedented strategy to HIV eradication: Lock-in and apoptosis. Sci Rep 2017; 7: 8957. doi:10.1038/s41598-017-09129-w

26. Chandrasekar Raju, Sivagami B et al., Validation of a Stability-Indicating Analytical Method Development for Simultaneous Estimation of Sodium Phenylbutyrate and Taurursodiol in Bulk and Formulation Using UPLC Method. Iranian journal of pharmaceutical sciences 2025; 21: 70-81. DOI: https://doi.org/10.22037/ijps.v21i1.45528

27. Beludari Mahammad I, Chedela Hari K, Lingareddy Siva S R, Dara China B, Karimulla Shaik. Development and validation of a stability indicating analytical method for simultaneous determination of sodium phenylbutyrate and taurursodiol in bulk and formulation using reverse phase ultra performance liquid chromatography. Egyptian pharmaceutical journal 2024; 23: 264-71. doi: 10.4103/epj.epj_295_23

28. M Malyaadri1, N L Janaki. Analytical method development and validation of sodium phenyl butyrate and taurursodiol by using RP-UPLC in bulk and pharmaceutical dosage form. High Technology Letters 2024; 30: 164-77.

29. SK Karishma, B Anusha, Swetha Vegesna. Stability Indicating Method Devleopment and Validation for the Estimation of Sodium Phenyl Butyrate and Taurursodilol by Using RP-HPLC. African Journal of Biomedical Research 2024; 27: 15422-32. DOI:10.53555/AJBR.v27i4S.7699

30. Bhavani P, Prasada Rao K, Mohan S. Novel validated reversed-phase high-performance liquid chromatography method for determination of glucosamine, diacerein, and methyl sulfonyl methane in micro sample rat plasma and its application to pharmacokinetic and dissolution studies. Asian J Pharm Clin Res 2020; 13: 50-63.

31. Gomathy S, Narenderan S.T, Meyyanathan S.N, Gowramma B. Development and validation of hplc method for the simultaneous estimation of apigenin and luteolin in commercial formulation. J Crit Rev 2020; 7: 4785-90.

32. Supriya T, Naresh D, Vijaya Kumar G, Haneer MA. Stability indicating RP-HPLC method development and validation for simultaneous estimation of escitalopram and flupentixol pure and marketed formulation. Asian J Pharm Res 2018; 8: 4-10.

33. Mukta D. Naykode, Durgacharan A. Bhagwat, Swapnil D. Jadhav, Harinath N, et al. Analytical and bio analytical method for quantification of pure azilsartan, not its salt by RP-HPLC. Research J Pharm and Tech 2017; 10:708-14.

34. Mayanka Singh, Manoj Charde, Rajesh Shukla, Rita M.C. Determination of calcipotriene in calcipotriene cream 0.05% w/w by RP-HPLC method development and validation. Research J Pharm and Tech 2011; 4: 1219-23.

35. Ashutosh kumar S, Manidipa Debnath, Dr. Seshagiri Rao J.V.L.N, Dr. Gowri Sankar D. Development and validation of a sensitive RP-HPLC method for simultaneous estimation of rosuvastatin and fenofibrate in tablet dosage form by using PDA detector in Gradient mode. Research J Pharm and Tech 2016; 9: 549-54.

36. Manoranjani M. A study of method development, validation and forced degradation for simultaneous quantification of Cisplatin and Fluorouracil in bulk and pharmaceutical dosage form by RP-HPLC. J Pharm Sci Rev 2021; 13: 155-61.

37. Prasada Rao P T S R K. A study of method development and validation for simultaneous estimation of Pemetrexed and Cisplatin using RP-HPLC. J Pharm Sci Rev 2021; 13: 143-8.

38. Satyadev T N V S S. A new selective separation method development and validation of Cabozantinib and Nivolumab using HPLC. J Pharm Sci Rev 2021; 13: 188-92.

39. David Raju M. Development and validation of HPLC method for the determination of Lasmiditan drug in bulk and tablet dosage form. J Pharm Sci Rev 2021; 13: 170-3.

40. Ibrahim Baje Syed, Madhavi Nannapaneni. Bio analytical validation method for Capmatinib and Spartalizumab in rabbit plasma by using highly effective mass spectrophotometric method. Rasayan J Chem 2022; 15: 2748-55.

41. Shivani C.P, Maheshwari D. G, Development and validation of UV spectrometric and HPLC method for estimation of escitalopram oxalate and flupentixol dihydrochloride in combined dosage form. AJPTI 2016; 4: 59-70.

42. Shanmugasundaram P, Kamarapu S K. RP-HPLC method for the simultaneous estimation and validation of amlodipine besylate and atenolol in bulk and tablet dosage form in biorelevant dissolution medium (Fassif). Research J Pharm and Tech 2017; 10: 3379-85.

43. International conference on the harmonization. ICH harmonized tripartite guideline. Validation of analytical procedures: Text and methodology Q2(R1); 2005.

44. Abdul Raziq, Syed Umer Jan et al., Relative comparison of stability and degradation of methylcobalamine tablets of different brands at different storage settings. Int J App Pharm 2021; 13:171-75.

45. Syed Rafi, Kantipudi Rambabu. Stability indicating validated HPLC method for the determination of Aceclofenac and Misoprostol in bulk and pharmaceutical formulation. Int J Res Pharm Sci 2020;11: 7848-53.

46. Swati K, Abhishek P, Sushank S, Bothiraja C, Atmaram P. High-performance liquid chromatography for the simultaneous estimation of cefoperazone and sulbactam in rat plasma and its importance in therapeutic drug monitoring. Int J Pharm Pharm Sci 2020; 12: 92-97.

47. Anuradha Vejendla, Subrahmanyam Talari, Raju Moturu, S. N. Murthy Boddapati, A. Emmanuel Kola. Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR. Futur J Pharm Sci 2021; 7: 1-18. http:// creat iveco mmons. org/ licen ses/ by/4.0/.

48. Charu Pandya P, Sadhana Rajput J. Development and validation of stability indicating method RP-HPLC method of Acotiamide. Int J Pharm Pharm Sci 2018; 10: 1-8.

49. Birva Athavia A, Zarna Dedania R et.al., Stability indicating HPLC method for determination of Vilazodone hydrochloride. Int J Curr Pharm Res 2017; 9: 123-29.